Monash IVF Group (MVF.AX) Osake Kurssi
Monash IVF Group Kurssi
Liikevaihto on kasvanut 8,2 % vuodessa viimeisten 16 vuoden aikana 269,46 M AUD:een. Osakekohtainen tulos on kasvanut 4,6 % vuodessa viimeisten 12 vuoden aikana. Monash IVF Groupn nettomarginaali on nyt 2,8 %, laskenut 9,6 %:sta muutama vuosi sitten. Monash IVF Groupn osinkotuotto on tällä hetkellä noin 1,60 %. Jakosuhde on noin 102 % tuloksesta. Analyytikoiden mediaanitavoitehinta on 0,86 AUD, eli yli nykyhintaa 14,2 %. 10 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Monash IVF Group osakekurssi
Monash IVF Group liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Monash IVF Group -osakkeesta
Monash IVF Group Ltd is primarily active in the healthcare and biotechnology industries.
Some of the main competitors of Monash IVF Group Ltd in the market include Virtus Health Limited, Healthscope Limited, and Genea Limited. These companies also operate in the fertility services sector and compete with Monash IVF Group Ltd in providing reproductive and infertility treatments.
Monash IVF Group Ltd operates as a leading fertility provider in Australia. The company's business model focuses on offering a comprehensive range of assisted reproductive services. Monash IVF Group specializes in fertility treatments, including in vitro fertilization (IVF), sperm and egg donation, genetic testing, and surrogacy. With a dedicated team of specialists and advanced laboratory facilities, Monash IVF Group aims to help individuals and couples achieve their dream of having a family. By combining cutting-edge technology, personalized care, and research advancements, the company strives to deliver the highest quality fertility care to its patients.
Monash IVF Group Ltd, founded in 2000, is a leading Australian fertility services provider. Specializing in assisted reproductive technology and treating infertility, the company has a rich history of pioneering advancements. Monash IVF Group Ltd operates a network of fertility clinics, offering comprehensive services such as in vitro fertilization, fertility testing, and sperm and egg donation. With a team of highly skilled specialists, the company is committed to delivering exceptional patient care and achieving strong success rates in fertility outcomes. Monash IVF Group Ltd has grown to become a trusted name in the fertility industry, consistently providing hope and support to individuals and couples seeking to start or expand their families.
Monash IVF Group Ltd has achieved several significant milestones. The company has a strong track record of delivering high success rates in assisted reproductive technologies such as in vitro fertilization (IVF) and has assisted in the birth of over 30,000 babies. Monash IVF Group Ltd has also pioneered innovative fertility treatments and technologies, including the development of genetic testing for embryos and advancements in egg freezing techniques. The company's commitment to research and clinical excellence has made them a leading player in the fertility industry, earning them a reputation for delivering exceptional patient outcomes and maintaining a position at the forefront of reproductive medicine.
Monash IVF Group Ltd primarily operates in Australia and Malaysia. Australia is its main market, where it has multiple clinics located across the country. Additionally, the company has a significant presence in Malaysia, offering fertility services through its strategic partnership with Sunfert International. Monash IVF Group Ltd's focus on these countries and regions allows it to provide comprehensive reproductive and fertility services to patients, including in vitro fertilization (IVF), genetic testing, and other related treatments.
Monash IVF Group Ltd represents values of excellence, innovation, and patient-centered care. With a corporate philosophy focused on fulfilling the dreams of parenthood, Monash IVF Group Ltd is dedicated to providing cutting-edge fertility treatments and personalized support to couples and individuals. By leveraging its extensive experience and technological advancements, the company strives to deliver superior reproductive medicine services. Monash IVF Group Ltd maintains its commitment to the highest ethical standards, transparency, and fostering a compassionate and inclusive environment for its patients.
Analyytikot asettavat tällä hetkellä Monash IVF Group-osakkeelle keskimääräisen tavoitehinnan 0,85 AUD (mediaani: 0,86 AUD), mikä merkitsee +12,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Monash IVF Group-osaketta: 6 suosittaa ostoa, 4 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla Monash IVF Group-osake noteerataan hintaan 0,47 EUR (0,75 AUD).
Monash IVF Group-osake (MVF.AX) on listattuna 3 pörssissä, muun muassa: ASX (MVF.AX), Frankfurt (MIS.F), München (MIS.MU).
Monash IVF Group Ltd is an Australian-based company that specializes in providing assisted reproductive technology (ART) and the investigation and treatment of infertility. The company currently operates multiple fertility clinics and laboratories in Australia and New Zealand. The company offers a wide range of reproductive and fertility services that focus on meeting the specific needs and requirements of each customer. This includes in-vitro fertilization (IVF), intrauterine insemination (IUI), sperm and egg donation, as well as preimplantation diagnosis (PID) and genetic testing. Monash IVF Group has also specialized in researching and developing new technological approaches for assisted reproduction. This includes an extensive research program that focuses on investigating factors that influence fertility, such as lifestyle factors, environmental influences, and genetic predispositions. Another important aspect of the company is the education of doctors, nurses, and other professionals in assisted reproduction. Monash IVF Group offers a variety of courses, training, and workshops to constantly improve and develop knowledge and skills in the field of assisted reproductive technologies. In addition to its clinical services and research program, Monash IVF Group also operates its own diagnostic laboratory that offers a wide range of tests for diagnosing infertility. This includes hormone analysis, semen analysis, and genetic testing. The company is also able to extend its services to international customers. Monash IVF Group has a strong presence in Asia and currently operates clinics in Malaysia and Singapore. Overall, Monash IVF Group has a comprehensive business model that focuses on providing high-quality reproductive and fertility services, conducting innovative research programs, educating professionals, and expanding international markets. The company is well-positioned to grow its customer base and expand its range of services and products to meet the changing demands in the field of assisted reproductive technology.
liikevaihto Monash IVF Group on 269,46 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Monash IVF Group on 7,43 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Monash IVF Group:n hinta-voitto-suhde (P/E) on tällä hetkellä 39,36. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Monash IVF Group-osakkeen arvostusta.
Monash IVF Group:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,08. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Monash IVF Group-osakkeen arvostuskennuslukuna.
Monash IVF Group:n Eulpool-laatuscore on 3/10.
Monash IVF Group:n ISIN on AU000000MVF3. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Monash IVF Group:n WKN on A116LZ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Monash IVF Group:n ticker on MVF.AX. Tämä pörssinoteeraus käytetään Monash IVF Group-osakkeiden kauppaan pörssissä.
Monash IVF Group osake
Monash IVF Group vertaisryhmä
Monash IVF Group Ticker
Monash IVF Group FIGI
Kaikki tunnusluvut ja syvällinen analyysi Monash IVF Group:sta
Meidän osakeanalyysimme Monash IVF Group-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Monash IVF Group:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: